Nafarelin

Summary

Nafarelin is a synthetic decapeptide analogue of gonadotropin‑releasing hormone (GnRH) that acts as a potent GnRH agonist. It is administered as a nasal spray and is approved in several countries for conditions that benefit from profound suppression of sex steroids, such as endometriosis, advanced prostate cancer, and central precocious puberty. Clinicians also use it off‑label to facilitate assisted reproductive technology cycles, to shrink uterine fibroids (leiomyomas), and to manage hormone‑sensitive disorders where temporary hypo‑estrogenic states are desired.

Mechanism of Action

When given continuously, nafarelin initially stimulates pituitary GnRH receptors, causing a brief rise in luteinising hormone (LH) and follicle‑stimulating hormone (FSH). This is followed by receptor desensitisation and down‑regulation, leading to a marked fall in LH and FSH secretion. The downstream effect is a rapid decline in ovarian or testicular production of estrogen and testosterone, creating a hypo‑gonadal hormonal environment that underlies its therapeutic actions.

What the Research Shows

A meta‑analysis of nine randomized IVF trials (1,014 women) found pregnancy rates per embryo transfer with nafarelin to be comparable to other GnRH agonists, while requiring fewer ampoules of gonadotropins and fewer stimulation days. Reviews of endometriosis management cite nafarelin as an effective medical option alongside leuprolide and goserelin. In leiomyoma studies involving 602 patients, intranasal nafarelin (50‑400 µg BID for 3‑6 months) consistently reduced estrogen levels, shrank fibroids, controlled menorrhagia, and improved hemoglobin, with bone mineral density loss that recovered after treatment cessation. General overviews note its approved uses (prostate cancer, endometriosis, precocious puberty) and investigational roles in other endocrine disorders. Experimental iontophoresis research demonstrates that nafarelin can be delivered transdermally, though clinical relevance remains unproven.

Reported Benefits

Clinical evidence shows that nafarelin effectively suppresses estrogen, leading to reduced uterine fibroid size and bleeding, improved hematologic parameters, and relief of dysmenorrhoea. In IVF cycles it provides pregnancy outcomes equivalent to other GnRH agonists while lowering gonadotropin requirements. For endometriosis, it offers symptom control comparable to other GnRH analogues. The nasal route allows non‑invasive administration, and adverse effects are generally mild and reversible.

Limitations of the Evidence

Evidence is strongest for short‑term use in fibroids, endometriosis, and IVF protocols; long‑term safety data are limited. Bone mineral density loss during treatment, although reversible, raises concerns for extended therapy. Cost‑effectiveness of reduced gonadotropin use has not been conclusively demonstrated. Data on novel delivery methods such as iontophoresis are pre‑clinical, and many potential indications remain investigational.

Safety Considerations

The most frequently reported adverse events are hypo‑estrogenic symptoms, especially hot flushes and mild vasomotor complaints. Bone mineral density may decline during 3‑6 months of therapy but typically returns to baseline within six months after discontinuation. Menstrual suppression can lead to amenorrhoea and associated mood changes. Overall tolerability is good, and adverse effects usually resolve after stopping the drug.

How It Is Administered

Nafarelin is supplied as a nasal spray; typical dosing regimens reported in studies range from 50 to 400 µg administered twice daily for periods of three to six months, depending on the indication (e.g., fibroid shrinkage or endometriosis control). In assisted reproduction protocols, dosing is adjusted to fit long or short stimulation cycles. Experimental transdermal iontophoresis delivery has been explored but is not an approved formulation.

Routes of Administration

Goals & Uses

• Treatment of endometriosisGynecologyHigh
• Treatment of central precocious pubertyPediatric EndocrinologyHigh
• Uterine fibroids (leiomyomata) managementGynecologyModerate
• Estrogen suppression for endometriosis‑related painGynecologicalHigh
• Ovarian stimulation suppression in assisted reproductionReproductive MedicineModerate
• Testosterone suppression in advanced prostate cancerOncologyHigh

Contraindications

• Known hypersensitivity to Nafarelin or excipientsAllergyHigh
• PregnancyPopulationHighPotential fetal risk or insufficient safety data
• BreastfeedingPopulationHighPotential transfer into breast milk or insufficient safety data
• Undiagnosed abnormal vaginal bleedingGynecologyHigh
• Hypersensitivity to GnRH or GnRH analogsAllergy / ImmunologyHigh
• Osteoporosis or significant bone lossMusculoskeletalModerate

Adverse Effects

• Nasal irritation / rhinitisLocal/NasalCommon
• Nasal irritationLocal/NasalCommon
• HeadacheNeurologicCommonPain in the head or upper neck
• Decreased bone mineral densityMusculoskeletalCommon
• Hot flashesEndocrine / VasomotorCommon
• Mood changes / depressionPsychiatricUncommon
• Bone mineral density lossSkeletalRare
• Vaginal drynessGynecologicCommon

Drug Interactions

• Estrogen replacement therapyModerate
• Nasal decongestants (topical)Moderate
• Sex hormone preparations (estrogens, androgens, progestogens)Moderate
• Cytochrome P450 inhibitors (e.g., ketoconazole)Low

Population Constraints

• Pediatric patientsAgeRelative
• Patients with history of osteoporosisMusculoskeletalRelative
• Patients with chronic nasal conditionsENTRelative
• Pediatric patients under 2 yearsAgeAbsolute
• Elderly patients with severe hepatic impairmentOrgan FunctionRelative
• Adolescents with central precocious pubertyPediatricRelative

Regulatory Status

• European UnionApprovedApproved: endometriosis‑related painAvailable as nasal spray; no approved indication for prostate cancer in EU.
• United StatesApprovedApproved: endometriosis‑related pain, palliative treatment of advanced prostate cancerApproved as nasal spray (Synarel) for endometriosis; depot injection approved for prostate cancer.
• United KingdomApprovedApproved: Endometriosis, Central precocious pubertyApproved by MHRA; marketed as Synarel in the UK.

Administered as a nasal spray (Synarel) in the US; depot injection formulations are available in some markets for prostate cancer.

Evidence & Sources

• Efficacy of nafarelin in assisted reproductive technology: a meta-analysis
  Journal ArticleHighWong JM, et al.2001-01-01T00:00:00.000000Z
• Endometriosis: treatment strategies
  Journal ArticleModerateValle RF, Sciarra JJ2003-01-01T00:00:00.000000Z
• Clinical use of nafarelin in the treatment of leiomyomas. A review of the literature
  Journal ArticleModerateMinaguchi H, Wong JM, Snabes MC2000-01-01T00:00:00.000000Z
• Uses of GnRH agonists
  Journal ArticleModerateGarner C1994-01-01T00:00:00.000000Z
• Hereditary Coproporphyria
  Journal ArticleModerateAdam MP, et al.1993-01-01T00:00:00.000000Z
• Transdermal iontophoresis
  Journal ArticleModerateBatheja P, Thakur R, Michniak B2006-01-01T00:00:00.000000Z

Frequently Asked Questions